Allogeneic Placental-Derived Product Candidates
Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic products for indications where the demonstrated properties of such cells could provide an advantage, both in terms of development (sourcing and proliferation) and potential efficacy (affinity). In selecting indications, we evaluate where the biological properties of the placenta positions our products for success, and where there is a clearly defined regulatory pathway that provides the potential for accelerated development to address unmet patient need.
Developing first-in-class / best-in-class cellular and regenerative assets
Advanced Biomaterials Pipeline
| Advanced Biomaterials | Indication | Discovery | Regulatory | Commercialization | |
|---|---|---|---|---|---|
| Amniotic Membrane Allograft | Wound Care |
|
|||
| Tri-Layer Amniotic Membrane Allograft | Wound Care |
|
|||
| Tri-Layer Amniotic Membrane Allograft | Ocular Protective Cover |
|
|||
| Amniotic Membrane Allograft | Wound Care |
|
|||
| Tri-Layer Amniotic Membrane Allograft | Wound Care |
|
|||
| Placental Connective Tissue Matrix | Wound Care |
|
|||
| Celularity Tendon Wrap (CTW) | Surgical Tendon Management |
|
|||
| FUSE Bone Void Filler | Orthopedics / Bone, Spine, Dental |
|
|||
| Celularity Placental Matrix (CPM) | Soft Tissue Management |
|
|||
Clinical Research Pipeline
| Platform | Candidate | Optimization | Indications | Discovery | Pre-clinical | Phase 1/2 | Phase 3 |
|---|---|---|---|---|---|---|---|
| MLASC | PDA-001/002 | Unmodified | Autoimmune (Crohn's) & DFU |
|
|||
| MLASC | PDA-002 | Unmodified | FSHD |
|
|||
| pT | Unmodified | CAR + Persistence + Stealth | Solid Tumor |
|
|||
| pT/ pNK | Undisclosed | CAR + Persistence + Stealth | Autoimmune Disease |
|
|||
Developing first-in-class / best-in-class cellular and regenerative assets
| Advanced Biomaterials | Indication | ||
| Celularity Tendon Wrap (CTW) | Tendon | ||
| Discovery | Regulatory | Commercialization | |
|
|
|||
| FUSE Bone Void Filler | Bone, Spine, Dental | ||
| Discovery | Regulatory | Commercialization | |
|
|
|||
| Celularity Placental Matrix (CPM) | Wound Covering | ||
| Discovery | Regulatory | Commercialization | |
|
|
|||
| Cellular Medicine | Optimization | ||
| MLASC | Unmodified | ||
| Therapeutic Areas | Pre-Clinical | IND-Enabling | |
|
|
|||
| MLASC | Autoimmune & Degenerative Disease | ||
| Therapeutic Areas | Pre-Clinical | IND-Enabling | |
|
|
|||
| T / NK | CAR + Persistence + Stealth | ||
| Therapeutic Areas | Pre-Clinical | IND-Enabling | |
|
|
|||
| T | CAR + Persistence + Stealth | ||
| Therapeutic Areas | Pre-Clinical | IND-Enabling | |
|
|
|||
| NK | Unmodified / CAR + Persistence + Stealth + Reduced Lymphodepletion | ||
| Therapeutic Areas | Pre-Clinical | IND-Enabling | |
|
|
|||
Developing Therapies for a Range of Diseases
Celularity is investigating allogeneic therapies that are ready-to-use and eliminate the need for matching patients with donors.
We believe we are only in the early stages of unlocking the full potential of the Celularity IMPACT platform (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).